R&D in Cutting-Edge Technologies, New Products and New Businesses
First written in FY2016. 20 of 32 entries say "Restated". Latest entry: 2026-10-09.
- FY2026AdvancedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥383 million, all of which related to company-wide activities. The Group conducted the following R&D for sales purposes: (1) R&D on AI-agent applications operating on BizInsight (2) R&D on the utilisation of meeting-record data, including mobile support and summary templates (3) R&D to enhance the functions of the large-file transfer service eTransporter (4) Research into new technologies, primarily related to generative AI, and market research for planning new services」
R&D expenses declined from ¥501 million in the previous fiscal year to ¥383 million, while the R&D themes have been specified to include the AI agent on BizInsight, utilisation of meeting-record data, enhancements to eTransporter, and research into new generative-AI technologies and markets, among others. - FY2026-H1RestatedAnnual report
「The Group's total R&D expenses for the six-month interim consolidated accounting period were ¥153 million. There were no material changes in the status of the Group's R&D activities during the six-month interim consolidated accounting period.」
The company recorded ¥153 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥501 million, all of which related to company-wide activities. The Group conducted the following R&D for sales purposes: (1) R&D to validate demand for generative AI in on-premises environments and develop solutions (2) R&D on solutions to turn speech and other audio data into reusable data assets and promote data utilisation (3) R&D on solutions to strengthen sales at large restaurant chains and similar businesses (4) R&D on solutions to promote digitalisation in manufacturing and logistics (5) Implementation of AI analysis functions in the medical incident management system (6) Enhancement of functions and performance to increase users of the health-management promotion platform (7) Identification of issues and consideration of measures related to next-generation water utility DX (8) R&D on policy trends, including healthcare DX (9) R&D to enhance product functions, including next-generation dental appointment systems and other technology development in growth areas.」
R&D expenses increased from ¥236 million in the previous fiscal year to ¥501 million. The R&D scope has been further specified and expanded to include generative AI, audio-data utilisation, manufacturing and logistics, medical AI, health management, water utility DX and dental appointment systems, among others. - FY2024AdvancedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥236 million. The Group conducted the following R&D for sales purposes: (1) R&D on technology to improve speech-to-text transcription accuracy using generative AI (2) R&D on large language models and generative-AI applications in on-premises environments (3) R&D on image-analysis technology for accurate handwashing in areas equipped for rinsing (4) R&D on fall-detection technology using sensors built into smartphones and other devices」
R&D expenses were ¥236 million, with the R&D scope specified and expanded to include generative AI and large language models, image analysis and fall detection. - FY2024-Q2RestatedAnnual report
「The Group's total R&D expenses for the six months ended the second quarter were ¥107 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded ¥107 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2024-Q1RestatedAnnual report
「The Group's total R&D expenses for the three months ended the first quarter were ¥62 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded ¥62 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2023AdvancedAnnual report
「The Group's total R&D expenses for the fiscal year were ¥190 million. The Group conducted the following R&D for sales purposes: (1) R&D using machine-learning models for image analysis and related applications, including object detection and contactless UI development (2) R&D using machine-learning models for natural-language analysis and related applications, including report analysis and text summarisation (3) R&D on predictive models using numerical analysis, including demand and sales forecasting (4) R&D aimed at further improving the accuracy of autonomous navigation (PDR and VDR) (5) R&D on a cloud-based medical safety management system for clinics (6) R&D on an app aimed at extending healthy life expectancy in local communities (7) Verification of the effectiveness of AI functions for analysing medical incident data」
The company recorded ¥190 million in R&D expenses and has specified and expanded its R&D scope beyond its existing image-analysis, natural-language and predictive-model work to include a cloud-based medical safety management system, an app to extend healthy life expectancy and the use of AI in medical incident data analysis. - FY2023-Q1RestatedAnnual report
「The Group's total R&D expenses for the three months ended the first quarter were ¥32 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded ¥32 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2022-Q3RestatedAnnual report
「The Group's total R&D expenses for the nine months ended the third quarter were ¥137 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company recorded ¥137 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2022-Q1RestatedAnnual report
「The Group's total R&D expenses for the three months ended the first quarter were ¥32 million. There were no material changes in the status of the Group's R&D activities during the three months ended the first quarter.」
The company recorded ¥32 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2021RestatedAnnual report
「The Group has promoted its R&D activities primarily to continuously pursue cutting-edge technologies and develop new products for expanding into new businesses. The projects undertaken in the previous fiscal year continued to perform steadily, and the Group's total R&D expenses for the fiscal year were ¥118 million. The Group conducted the following R&D for sales purposes: (1) R&D using machine-learning models for image analysis and related applications, including object detection and contactless UI development (2) R&D using machine-learning models for natural-language analysis and related applications, including report analysis and text summarisation (3) R&D on predictive models using numerical analysis, including demand and sales forecasting (4) R&D aimed at the practical and commercial application of autonomous navigation (PDR and VDR) (5) R&D aimed at the practical and commercial application of services using facial recognition and speech-recognition technologies」
The company recorded ¥118 million in R&D expenses and continues R&D in growth areas including image analysis, natural-language analysis, predictive models, autonomous navigation, facial recognition and speech recognition. No newly completed milestones are specified. - FY2021-Q3RestatedAnnual report
「The Group's total R&D expenses for the nine months ended the third quarter were ¥101 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company stated that R&D expenses for the nine months ended the third quarter were ¥101 million and that there were no material changes in the status of its R&D activities. - FY2021-Q2RestatedAnnual report
「The Group's total R&D expenses for the six months ended the second quarter were ¥68 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded ¥68 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2020AdvancedAnnual report
「The projects undertaken in the previous fiscal year continued to perform steadily, and the Group's total R&D expenses for the fiscal year were ¥155 million. The Group conducted the following R&D for sales purposes: (1) R&D using machine-learning models for image analysis and related applications, including damage detection, scoring of human movements and contactless UI development; (2) R&D using machine-learning models for natural-language analysis and related applications, including minutes preparation, report analysis and text summarisation; (3) R&D on predictive models using numerical analysis, including demand and sales forecasting; (4) R&D on the VDR library; (5) R&D aimed at the practical and commercial application of pedestrian dead reckoning (PDR); (6) R&D aimed at the practical and commercial application of reception systems using facial recognition and speech-recognition technologies; (7) R&D on transmission systems for large-format displays at sports venues; and (8) technology development in growth areas, including new functions for the file-sharing system and enhanced Excel aggregation functions.」
The company recorded ¥155 million in R&D expenses and has specified and expanded its R&D scope to include predictive models using numerical analysis, pedestrian dead reckoning, and reception systems using facial recognition and speech recognition, among others. - FY2020-Q3RestatedAnnual report
「The Group's total R&D expenses for the nine months ended the third quarter were ¥109 million. There were no material changes in the status of the Group's R&D activities during the nine months ended the third quarter.」
The company recorded ¥109 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2020-Q2RestatedAnnual report
「The Group's total R&D expenses for the six months ended the second quarter were ¥78 million. There were no material changes in the status of the Group's R&D activities during the six months ended the second quarter.」
The company recorded ¥78 million in R&D expenses and stated that there were no material changes in the status of its R&D activities. - FY2020-Q1RestatedAnnual report
「The Group's total research and development expenses for the cumulative first quarter were ¥39 million. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company recorded ¥39 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2019AdvancedAnnual report
「Planning projects undertaken in the previous fiscal year remained firm, and the Group's total research and development expenses for the consolidated fiscal year were ¥157 million. For commercial sale, the company conducted technology development in growth fields, including research and development using learning models for image analysis, such as defect detection, scoring human movements and developing contactless user interfaces; research and development using learning models for natural language analysis, such as preparing minutes, analyzing reports and summarizing text; new functions for file-sharing systems; and enhanced Excel aggregation functions.」
Research and development expenses were ¥157 million, covering specific research areas including learning models for image and natural language analysis and functional enhancements to file-sharing systems. - FY2019-Q3RestatedAnnual report
「The Group's total research and development expenses for the cumulative third quarter were ¥125 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter.」
The company recorded ¥125 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2019-Q2AdvancedAnnual report
「In May, the company entered into a business alliance with Rist, an AI venture originating at Kyoto University, and began joint research and development using AI technologies such as deep learning and machine learning. In September, it entered into a capital and business alliance with パルスボッツ株式会社, which has a track record in robot-related communication engines and other technologies, and is working jointly to develop new services and systems using an engine developed by that company.」
In addition to joint AI research and development with Rist, the company entered into a capital and business alliance with パルスボッツ and began and is advancing joint development of new services and systems using its engine, giving concrete form to its research and development and new product development initiatives. - FY2019-Q1AdvancedAnnual report
「In May, the company entered into a business alliance agreement with Rist, an AI venture originating at Kyoto University, and began joint research and development.」
The company stated a new research and development milestone: entering into a business alliance agreement with the AI venture Rist and beginning joint research and development. Research and development expenses were ¥40 million for the cumulative first quarter. - FY2018AdvancedAnnual report
「Planning projects undertaken in the previous fiscal year remained firm, and the Group's total research and development expenses for the consolidated fiscal year were ¥65 million. Market launches have been carried out for (1), (2) and (4). For (5), the company established a consortium and is conducting promotional activities across corporate and industry boundaries.」
Research and development expenses were ¥65 million. The company continues to develop remote health support, regional healthcare coordination and large-capacity file transfer systems, among others. In addition to multiple market launches, the company established a consortium for services in the FA and PA fields and advanced to promotional activities. - FY2018-Q3RestatedAnnual report
「The Group's total research and development expenses for the cumulative third quarter were ¥37 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter.」
Research and development expenses for the cumulative third quarter were ¥37 million. The company stated that there were no material changes in the status of its research and development activities. - FY2018-Q2RestatedAnnual report
「The Group's total research and development expenses for the cumulative second quarter were ¥27 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter.」
Research and development expenses for the cumulative second quarter were ¥27 million, and the company stated that there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「The Group's total research and development expenses for the cumulative first quarter were ¥2 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company recorded ¥2 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2017AdvancedAnnual report
「Planning projects undertaken in the previous fiscal year remained firm, and the Group's total research and development expenses for the consolidated fiscal year were ¥147 million. • System solutions services business: research and development of products for commercial sale」
The company recorded ¥147 million in research and development expenses, and multiple medical and healthcare systems reached the market launch, early implementation or trial-operation stage. - FY2017-Q3RestatedAnnual report
「The Group's total research and development expenses for the cumulative third quarter were ¥125 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative third quarter.」
The company recorded ¥125 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2017-Q2RestatedAnnual report
「The Group's total research and development expenses for the cumulative second quarter were ¥91 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative second quarter.」
The company recorded ¥91 million in research and development expenses and stated that there were no material changes in the status of its research and development activities. - FY2017-Q1RestatedAnnual report
「The Group's total research and development expenses for the cumulative first quarter were ¥56 million, relating to the system solutions services business. There were no material changes in the status of the Group's research and development activities during the cumulative first quarter.」
The company stated that research and development expenses were ¥56 million for the quarter and that there were no material changes in the status of its research and development activities. - FY2016First statedAnnual report
「The Group's research and development activities have primarily focused on continuously exploring advanced technologies and developing new products to launch new businesses. Planning projects undertaken in the previous fiscal year remained firm, and the Group's total research and development expenses for the consolidated fiscal year were ¥263 million.」
The company recorded ¥263 million in research and development expenses, covering multiple fields including genetic testing, education, construction equipment rental, file servers and health management for affluent Chinese consumers.